How weight-loss drugs are changing sleep apnea care and what clinicians must decide next

# Why this matters now The standard approach to obstructive sleep apnea (OSA) has long been mechanical: positive airway pressure, oral appliances, or surgery. A multidisciplinary editorial led by Timothy I. Morgenthaler in the Journal of Clinical Sleep Medicine says that incretin-based weight-loss drugs, especially tirzepatide, change that frame. Because these drugs reduce the adipose burden that helps collapse the airway, they can be disease-modifying for some patients with obesity-related OSA.

# What the evidence says

# The overlap model clinicians should use

# Decisions sleep clinicians must make The editorial avoids calling for every sleep physician to become an obesity specialist. Instead it sets a narrower task: develop enough competence and infrastructure to guide patients through weight-based therapies that affect their OSA. Specific decisions include:

• Providing nonstigmatizing counseling about how weight loss may improve but not necessarily eliminate OSA.
• Determining when to prescribe, when to co-manage with obesity specialists, and when to refer for bariatric surgery.
• Integrating drug therapy with PAP and other established treatments and arranging objective reassessment of breathing during sleep.

# Practical barriers to integration The editorial lists tangible obstacles that will shape implementation:

• Scope of practice uncertainty: prescribing obesity drugs is legally accessible to physicians, which blurs specialty boundaries.
• Limited training: many sleep clinicians lack formal training in pharmacologic weight management.
• Weight stigma: clinicians must avoid stigmatizing language and approaches when discussing weight.
• Operational burden and cost: arranging medication monitoring, insurance navigation, and follow-up adds clinic work.
• Access and equity: not all patients will have access to these drugs because of coverage and affordability issues.

# What clinicians and programs can do next Programs should consider pragmatic steps: create referral partnerships with obesity medicine, train clinicians in basic pharmacologic weight management and safety monitoring, build protocols for co-managing PAP with drug therapy, define outcome measures and reassessment timelines, and set clear counseling templates that explain realistic expectations about symptom change. The editorial emphasizes competence, structure, and humility as guiding principles.

# Bottom line Incretin-based weight-loss drugs—typified by tirzepatide—change how obesity contributes to OSA and force sleep medicine to decide which parts of obesity care belong in the specialty. The choice is operational and clinical: adopt structured, competence-based approaches to identify eligible patients, manage therapy responsibly, and maintain established airway treatments while monitoring outcomes.